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Abstract 
Ph-like ALL is characterized by several 
chromosomal translocations involving activating 
cytokine receptor or tyrosine kinase such as CRLF2, 
ABL1, JAK2, and PDGFRB (Robert K.G et al, 
2014). Recent increasing evidences suggest that 
patients with Ph-like ALL bearing PDGFRB 
translocation are potentiated to respond to tyrosine 
kinase inhibitors. Thus, this translocation should be 
included within the molecular companion 
diagnostics to facilitate tailor-made cancer therapy. 
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Disease 
Ph-like acute lymphoblastic leukemia 
Clinics 
The patient is an 8-year-old male with B-ALL. Initial 
cytogenetics analysis showed a 45, XY, -7, add (12) 
(p13). RNA sequence analysis identified a novel 
translocation of ATF7IP/PDGFRB (Kobayashi K.et 
al, 2013). He showed good response to standard risk 
ALL therapy, but he relapsed even in the 
continuation of the maintenance chemotherapy at 26 
months after the diagnosis. He received 3 course of 
salvage therapies following by stem cell 
transplantation. Second generation dasatinib was 
commenced with the minimum residual disease 
(MRD) at day 60 post-transplant. The therapeutic 
response was prompt, with the disappearance of 
genomic-PCR based on MRD within 3 months, and 
he has maintained complete molecular remission for 
12 months (Kobayashi K.et al, 2014). 
Prognosis 
As was shown in Ph-like ALL bearing PDGFRB 
translocation, i.e. EBF1/PDGFRB, t(5;12)(q33;p13) 
ATF7IP/PDGFRB translocation seems response to 
TKI. 
Cytogenetics 
Cytogenetics morphological 
Banding cytogenetics revealed 45, XY, -7, add (12) 
(p13). The mRNA sequence analysis identified an 
in-frame transcript fusing exon 13 of ATF7IP with 
exon 11 of PDGFRB, i.e. t(5;12)(q33;p13). 
Genes involved and 
proteins 
PDGFRB 
Location 
5q33 
Protein 
PDGFRB is a frequent target of chromosomal 
translocation in a broad spectrum of hematological 
malignancies. 
ATF7IP 
Location 
12p13 
Protein 
ATF7IP acts as transcriptional regulators and is 
frequently overexpressed in cancer cells modulating 
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telomerase TERT and TERC gene expression  (Liu, 
L. et al, 2009). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' ATF7IP-3' PDGFRB 
Fusion protein 
Description 
Forced expression of ATF7IP/PDGFRB, not wild-
type PDGFRB, conferred growth factor 
independence to murine Ba/F3cells, indicating that  
coiled-coil domain from 5' ATF7IP- would favour 
subsequent constitutive activation of the PDGFRB 
tyrosine kinase domain. 
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